Yongqian Shu

Author PubWeight™ 90.84‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010 5.92
2 A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. Nat Genet 2011 2.85
3 MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J Cancer Res Clin Oncol 2010 2.05
4 A functional genetic variant in microRNA-196a2 is associated with increased susceptibility of lung cancer in Chinese. Cancer Epidemiol Biomarkers Prev 2009 1.93
5 Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother 2010 1.82
6 miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010 1.76
7 Genetic variation of PSCA gene is associated with the risk of both diffuse- and intestinal-type gastric cancer in a Chinese population. Int J Cancer 2010 1.49
8 Association analyses identify multiple new lung cancer susceptibility loci and their interactions with smoking in the Chinese population. Nat Genet 2012 1.49
9 Common genetic variants on 5p15.33 contribute to risk of lung adenocarcinoma in a Chinese population. Carcinogenesis 2009 1.48
10 miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol 2011 1.48
11 Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer 2014 1.41
12 miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 2011 1.39
13 CHIP functions as a novel suppressor of tumour angiogenesis with prognostic significance in human gastric cancer. Gut 2012 1.22
14 Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review. PLoS One 2013 1.22
15 MiRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer. Cancer Biol Ther 2012 1.14
16 MicroRNA-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor. FEBS J 2012 1.10
17 Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials. Future Oncol 2013 1.08
18 Genetic polymorphisms in the precursor MicroRNA flanking region and non-small cell lung cancer survival. Am J Respir Crit Care Med 2010 1.06
19 Genome-wide association study of prognosis in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res 2012 1.05
20 A cluster of specified microRNAs in peripheral blood as biomarkers for metastatic non-small-cell lung cancer by stem-loop RT-PCR. J Cancer Res Clin Oncol 2011 1.05
21 Gene expression of the invasive phenotype of TNF-alpha-treated MCF-7 cells. Biomed Pharmacother 2009 1.03
22 Expression profile of multiple aquaporins in human gastric carcinoma and its clinical significance. Biomed Pharmacother 2010 1.02
23 The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J Thorac Oncol 2010 1.01
24 A 3'-untranslated region polymorphism in IGF1 predicts survival of non-small cell lung cancer in a Chinese population. Clin Cancer Res 2010 0.99
25 Targeting sarcoplasmic/endoplasmic reticulum Ca²+-ATPase 2 by curcumin induces ER stress-associated apoptosis for treating human liposarcoma. Mol Cancer Ther 2011 0.99
26 Systematic review and meta-analysis on the association between IL-1B polymorphisms and cancer risk. PLoS One 2013 0.99
27 MiR-135a targets JAK2 and inhibits gastric cancer cell proliferation. Cancer Biol Ther 2012 0.99
28 JNK/AP-1 pathway is involved in tumor necrosis factor-alpha induced expression of vascular endothelial growth factor in MCF7 cells. Biomed Pharmacother 2009 0.98
29 Genetic variants at 6p21.1 and 7p15.3 are associated with risk of multiple cancers in Han Chinese. Am J Hum Genet 2012 0.98
30 Sunitinib impairs the proliferation and function of human peripheral T cell and prevents T-cell-mediated immune response in mice. Clin Immunol 2009 0.97
31 Meta-analysis on the association between nonsteroidal anti-inflammatory drug use and lung cancer risk. Clin Lung Cancer 2011 0.97
32 Circulating microRNAs: possible prediction biomarkers for personalized therapy of non-small-cell lung carcinoma. Clin Lung Cancer 2011 0.96
33 NADPH oxidase subunit p22(phox)-mediated reactive oxygen species contribute to angiogenesis and tumor growth through AKT and ERK1/2 signaling pathways in prostate cancer. Biochim Biophys Acta 2013 0.95
34 The effects of cytokine-induced killer cells for the treatment of patients with solid tumors: a clinical retrospective study. J Cancer Res Clin Oncol 2012 0.95
35 miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2. Int J Mol Med 2013 0.95
36 The multi-targeted kinase inhibitor sunitinib induces apoptosis in colon cancer cells via PUMA. PLoS One 2012 0.95
37 Potentially functional polymorphisms in DNA repair genes and non-small-cell lung cancer survival: a pathway-based analysis. Mol Carcinog 2011 0.94
38 A novel approach to induce human DCs from monocytes by triggering 4-1BBL reverse signaling. Int Immunol 2009 0.93
39 Paeoniflorin suppress NF-kappaB activation through modulation of I kappaB alpha and enhances 5-fluorouracil-induced apoptosis in human gastric carcinoma cells. Biomed Pharmacother 2008 0.92
40 Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation. Anticancer Drugs 2011 0.92
41 Clinical perspective of afatinib in non-small cell lung cancer. Lung Cancer 2013 0.91
42 Polymorphisms of key chemokine genes and survival of non-small cell lung cancer in Chinese. Lung Cancer 2011 0.90
43 Polymorphisms in EGFR and VEGF contribute to non-small-cell lung cancer survival in a Chinese population. Carcinogenesis 2010 0.90
44 Genome-wide association study identifies a novel susceptibility locus at 12q23.1 for lung squamous cell carcinoma in han chinese. PLoS Genet 2013 0.90
45 Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel. Cancer Chemother Pharmacol 2013 0.90
46 Sequential transcatheter arterial chemoembolization, three-dimensional conformal radiotherapy, and high-intensity focused ultrasound treatment for unresectable hepatocellular carcinoma patients. J Biomed Res 2012 0.89
47 Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2013 0.89
48 Involvement of miR-143 in cisplatin resistance of gastric cancer cells via targeting IGF1R and BCL2. Tumour Biol 2014 0.89
49 miR-135a/b modulate cisplatin resistance of human lung cancer cell line by targeting MCL1. Pathol Oncol Res 2013 0.88
50 CD13+CD4+CD25hi regulatory T cells exhibit higher suppressive function and increase with tumor stage in non-small cell lung cancer patients. Cell Cycle 2009 0.88
51 Potentially functional polymorphisms in cell cycle genes and the survival of non-small cell lung cancer in a Chinese population. Lung Cancer 2010 0.87
52 Combine therapy of gefitinib and fulvestrant enhances antitumor effects on NSCLC cell lines with acquired resistance to gefitinib. Biomed Pharmacother 2012 0.86
53 A genetic polymorphism in pre-miR-27a confers clinical outcome of non-small cell lung cancer in a Chinese population. PLoS One 2013 0.86
54 Correlation between the expression levels of miR-1 and PIK3CA in non-small-cell lung cancer and their relationship with clinical characteristics and prognosis. Future Oncol 2014 0.86
55 Can plasma DNA monitoring be employed in personalized chemotherapy for patients with advanced lung cancer? Biomed Pharmacother 2012 0.86
56 Genetic variation in a microRNA-502 minding site in SET8 gene confers clinical outcome of non-small cell lung cancer in a Chinese population. PLoS One 2013 0.85
57 Genome-wide association study of survival in early-stage non-small cell lung cancer. Ann Surg Oncol 2014 0.85
58 Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer. BMC Cancer 2011 0.85
59 Aurora kinase inhibition induces PUMA via NF-κB to kill colon cancer cells. Mol Cancer Ther 2014 0.84
60 miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2. Anticancer Agents Med Chem 2014 0.83
61 Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials. Future Oncol 2014 0.83
62 Integrin α6(high) cell population functions as an initiator in tumorigenesis and relapse of human liposarcoma. Mol Cancer Ther 2011 0.83
63 Paeoniflorin modulates multidrug resistance of a human gastric cancer cell line via the inhibition of NF-κB activation. Mol Med Rep 2011 0.82
64 Axitinib, a selective inhibitor of vascular endothelial growth factor receptor, exerts an anticancer effect in melanoma through promoting antitumor immunity. Anticancer Drugs 2014 0.82
65 Enhanced charge transfer by gold nanoparticle at DNA modified electrode and its application to label-free DNA detection. ACS Appl Mater Interfaces 2014 0.81
66 WT1 promotes invasion of NSCLC via suppression of CDH1. J Thorac Oncol 2013 0.81
67 Double recognition of oligonucleotide and protein in the detection of DNA methylation with surface plasmon resonance biosensors. Biosens Bioelectron 2010 0.81
68 The property of methylated APC gene promotor and its influence on lung cancer cell line. Biomed Pharmacother 2008 0.81
69 Candidate variants at 6p21.33 and 6p22.1 and risk of non-small cell lung cancer in a Chinese population. Int J Mol Epidemiol Genet 2009 0.81
70 Activity of pemetrexed-based regimen as first-line chemotherapy for advanced non-small cell lung cancer with asymptomatic inoperable brain metastasis: a retrospective study. J Chemother 2015 0.80
71 Detection of microRNA SNPs with ultrahigh specificity by using reduced graphene oxide-assisted rolling circle amplification. Chem Commun (Camb) 2015 0.80
72 Tamoxifen inhibits proliferation and induces apoptosis in human hepatocellular carcinoma cell line HepG2 via down-regulation of survivin expression. Biomed Pharmacother 2008 0.80
73 Loss of SHP-2 activity in CD4+ T cells promotes melanoma progression and metastasis. Sci Rep 2013 0.80
74 Pemetrexed as the first-line therapy for Chinese patients with advanced non-squamous non-small-cell lung cancer. Biomed Pharmacother 2013 0.79
75 TNF-α-308 G>A polymorphism and colorectal cancer risk: a meta-analysis. Int J Colorectal Dis 2012 0.79
76 An electrochemical alkaline phosphatase biosensor fabricated with two DNA probes coupled with λ exonuclease. Biosens Bioelectron 2011 0.79
77 Phase II study of weekly irinotecan plus cisplatin in patients with previously untreated extensive-stage extrapulmonary small cell carcinoma. Onkologie 2011 0.79
78 Clinical significance of PIK3CA and survivin in primary adenosquamous lung carcinoma. Med Oncol 2014 0.78
79 Genetic variants in one-carbon metabolism-related genes contribute to NSCLC prognosis in a Chinese population. Cancer 2010 0.78
80 Thermal analysis in the rat glioma model during directly multipoint injection hyperthermia incorporating magnetic nanoparticles. J Nanosci Nanotechnol 2011 0.78
81 Effect of gefitinib challenge to initial treatment with non-small cell lung cancer. Biomed Pharmacother 2011 0.78
82 A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer. Biomed Pharmacother 2008 0.77
83 The study on newly developed McAb NJ001 specific to non-small cell lung cancer and its biological characteristics. PLoS One 2012 0.77
84 An electrochemical biosensor for clenbuterol detection and pharmacokinetics investigation. Talanta 2013 0.77
85 [Effect of recombinant adenovirus-p53 on growth and chemosensitivity of human lung adenocarcinoma cell lines]. Zhongguo Fei Ai Za Zhi 2006 0.77
86 Highly sensitive protein detection based on a novel probe with catalytic activity combined with a signal amplification strategy: assay of MDM2 for cancer staging. Chem Commun (Camb) 2013 0.76
87 [Current status and prospects of maintenance therapy in advanced stage non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi 2010 0.76
88 Xiao-Ai-Ping, a TCM Injection, Enhances the Antigrowth Effects of Cisplatin on Lewis Lung Cancer Cells through Promoting the Infiltration and Function of CD8(+) T Lymphocytes. Evid Based Complement Alternat Med 2013 0.75
89 CD137 ligand-mediated reverse signaling inhibits proliferation and induces apoptosis in non-small cell lung cancer. Med Oncol 2015 0.75
90 A simple and general approach to assay protease activity with electrochemical technique. Biosens Bioelectron 2013 0.75
91 [Clinical Study of Erlotinib in the Treatment of Patients with Advanced Stage Non-small Cell Lung Cancer.]. Zhongguo Fei Ai Za Zhi 2009 0.75
92 [microRNA expression profiling of side population cells in human lung cancer and preliminary analysis]. Zhongguo Fei Ai Za Zhi 2010 0.75
93 Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case report. Medicine (Baltimore) 2017 0.75
94 Recombinant human endostatin (endostar) decreased recurrent ascites, pleural fluid and ascitic VEGF in a case of advanced mesothelioma. J Chemother 2012 0.75
95 Delivery of paclitaxel and berbamine by polymeric carriers to cure gastric cancer. Oncol Res 2013 0.75
96 Andrographolide enhances cisplatin-mediated anticancer effects in lung cancer cells through blockade of autophagy. Anticancer Drugs 2017 0.75
97 Association between adjuvant docetaxel-based chemotherapy and breast cancer-related lymphedema. Anticancer Drugs 2017 0.75